Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nolpitantium · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Nolpitantium besylate | DRUG | - |
Inclusion Criteria: * Age at least 18 years * Ulcerative colitis of at least 6 months duration * Patient's ulcerative colitis should remain active while taking 5-ASA or sulfasalazine for at least 4 week * If taking corticosteroids, dose must be stable for at least 2 weeks prior to enrollment and no...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 10 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Upadacitinib |
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Tulisokibart |
| Pfizer Inc. | PFE | 8 | PHASE3 | Etrasimod |
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Filgotinib |
| Abivax SA Sponsored ADR | ABVX | 2 | PHASE3 | ABX464 |
| Bristol-Myers Squibb Company | BMY | 5 | PHASE2 | Ozanimod |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| AnaptysBio, Inc. | ANAB | 1 | PHASE2 | Rosnilimab |
| Palatin Technologies, Inc. | PTN | 1 | PHASE2 | PL8177 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | GSK4528287 |
| Xencor, Inc. | XNCR | 1 | PHASE1 | XmAb942 |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE2 | 627 |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
Nolpitantium is an investigational small molecule being studied for the treatment of Ulcerative Colitis, a form of Inflammatory Bowel Disease. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its efficacy and safety in patients with this condition.
Nolpitantium is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the drug's potential as a treatment for Ulcerative Colitis.
Nolpitantium is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The drug is being studied for the treatment of Ulcerative Colitis, and its safety and efficacy are still being evaluated in clinical trials.
Nolpitantium has been studied in one completed Phase 2 clinical trial with the identifier NCT00232258. This was a double-blind, placebo-controlled study that enrolled 307 participants with Ulcerative Colitis across multiple countries including Argentina, Belgium, Brazil, Canada, Chile, Czechia, Estonia, Hungary, Italy, Russia, Singapore, South Africa, Spain, and Sweden.
Nolpitantium is a small molecule drug being developed by Sanofi for the treatment of Ulcerative Colitis. Its specific molecular target has not been disclosed in available information. The drug is currently in Phase 2 clinical trials to evaluate its efficacy and safety in patients with this inflammatory bowel condition.